Citadel Advisors
SEEL

Citadel Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Citadel Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-317
Closed -$56.3K – 15644
2023
Q4 		$56.3K Buy
+317
New +$156K ﹤0.01% 11654
2023
Q1 		– Sell
-2
Closed -$5.86K – 15714
2022
Q4 		$6.12K Sell
2
-56
-97% -$195K ﹤0.01% 13940
2022
Q3 		$229K Sell
58
-121
-68% -$476K ﹤0.01% 10129
2022
Q2 		$468K Buy
179
+163
+1,019% +$425K ﹤0.01% 8793
2022
Q1 		$50K Buy
16
+11
+220% +$47.3K ﹤0.01% 12789
2021
Q4 		$31K Sell
5
-13
-72% -$99.8K ﹤0.01% 13471
2021
Q3 		$169K Buy
18
+6
+50% +$51.6K ﹤0.01% 12213
2021
Q2 		$125K Sell
12
-20
-63% -$329K ﹤0.01% 12708
2021
Q1 		$592K Buy
32
+12
+60% +$140K ﹤0.01% 9314
2020
Q4 		$123K Buy
20
+15
+300% +$58.9K ﹤0.01% 10085
2020
Q3 		$19K Buy
+5
New +$18K ﹤0.01% 9871
2020
Q2 		– Sell
-9
Closed -$17K – 10654
2020
Q1 		$17K Buy
+9
New +$33.5K ﹤0.01% 9338
2019
Q3 		– Sell
-3
Closed -$29K – 9876
2019
Q2 		$29K Buy
+3
New +$31.6K ﹤0.01% 8881
2019
Q1 		– Sell
-1
Closed -$24K – 10003
2018
Q4 		$24K Buy
+1
New +$34.7K ﹤0.01% 8686
2018
Q3 		– Hold
0
– – – 9098
2018
Q2 		– Sell
-1
Closed -$63K – 9390
2018
Q1 		$63K Buy
+1
New +$191K ﹤0.01% 7857
2017
Q4 		– Hold
0
– – – 7816
2017
Q3 		– Hold
0
– – – 7333
2017
Q2 		– Hold
0
– – – 7322
2017
Q1 		– Hold
0
– – – 6976
2016
Q1 		– Hold
0
– -$12K – 8193
2015
Q4 		– Hold
0
– – – 8216
2015
Q1 		– Hold
0
– – – 8925
2014
Q4 		– Hold
0
– – – 7768
2014
Q3 		– Hold
0
– – – 7625
2014
Q2 		– Hold
0
– – – 8378
2014
Q1 		– Hold
0
– – – 6929
2013
Q4 		– Hold
0
– – – 6805
2013
Q3 		– Hold
0
– – – 6534
2013
Q2 		– Hold
0
– – – 6363

Other funds holding SEEL

WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $381M AUM 21.36% 1-Year Est. Return

Citadel Advisors's SEEL Position: Q1 2024 in Review

Citadel Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2024, closing a stake of 317 shares — an estimated $56.3K sold.

Citadel Advisors first reported a position in SEEL in Q1 2018 and held it in 15 quarters. The position peaked at $592K in Q1 2021. 29 funds tracked by Wall St. Rank hold SEEL as of Q1 2024.

  • Citadel Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 317 Seelos Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $56.3K.
  • Citadel Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2018 and held it in 15 quarters.
  • Citadel Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $592K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.